These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34975325)

  • 1. Conjugate of ibrutinib with a TLR7 agonist suppresses melanoma progression and enhances antitumor immunity.
    Ren S; Wang X; Jin G
    Int J Biol Sci; 2022; 18(1):166-179. PubMed ID: 34975325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A chemical conjugation of JQ-1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation.
    Wang X; Yu B; Cao B; Zhou J; Deng Y; Wang Z; Jin G
    Int J Cancer; 2021 Jan; 148(2):437-447. PubMed ID: 32683685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.
    Hayashi T; Chan M; Norton JT; Wu CC; Yao S; Cottam HB; Tawatao RI; Corr M; Carson DA; Daniels GA
    Melanoma Res; 2011 Feb; 21(1):66-75. PubMed ID: 21030882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
    Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticle-Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses.
    Nuhn L; De Koker S; Van Lint S; Zhong Z; Catani JP; Combes F; Deswarte K; Li Y; Lambrecht BN; Lienenklaus S; Sanders NN; David SA; Tavernier J; De Geest BG
    Adv Mater; 2018 Nov; 30(45):e1803397. PubMed ID: 30276880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist.
    Hosoya T; Sato-Kaneko F; Ahmadi A; Yao S; Lao F; Kitaura K; Matsutani T; Carson DA; Hayashi T
    Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6836-E6844. PubMed ID: 29967183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel ibrutinib analogues to treat malignant melanoma.
    Ren S; Wang X; Song J; Jin G
    Bioorg Chem; 2021 Dec; 117():105419. PubMed ID: 34689082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acidic pH-responsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapy.
    Kim H; Sehgal D; Kucaba TA; Ferguson DM; Griffith TS; Panyam J
    Nanoscale; 2018 Nov; 10(44):20851-20862. PubMed ID: 30403212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Therapy with a TLR7 Agonist and a BRD4 Inhibitor Suppresses Tumor Growth via Enhanced Immunomodulation.
    Liu YS; Wang JX; Jin GY; Hu MH; Wang XD
    Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune.
    Jiang Z; Cai G; Liu H; Liu L; Huang R; Nie X; Gui R; Li J; Ma J; Cao K; Luo Y
    J Nanobiotechnology; 2024 May; 22(1):296. PubMed ID: 38811964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice.
    Ma F; Zhang J; Zhang J; Zhang C
    Cell Mol Immunol; 2010 Sep; 7(5):381-8. PubMed ID: 20543857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.
    Singh M; Khong H; Dai Z; Huang XF; Wargo JA; Cooper ZA; Vasilakos JP; Hwu P; Overwijk WW
    J Immunol; 2014 Nov; 193(9):4722-31. PubMed ID: 25252955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy.
    Kim SY; Kim S; Kim JE; Lee SN; Shin IW; Shin HS; Jin SM; Noh YW; Kang YJ; Kim YS; Kang TH; Park YM; Lim YT
    ACS Nano; 2019 Nov; 13(11):12671-12686. PubMed ID: 31589013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
    Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
    Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity.
    Schmid D; Park CG; Hartl CA; Subedi N; Cartwright AN; Puerto RB; Zheng Y; Maiarana J; Freeman GJ; Wucherpfennig KW; Irvine DJ; Goldberg MS
    Nat Commun; 2017 Nov; 8(1):1747. PubMed ID: 29170511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.
    Adlard AL; Dovedi SJ; Telfer BA; Koga-Yamakawa E; Pollard C; Honeychurch J; Illidge TM; Murata M; Robinson DT; Jewsbury PJ; Wilkinson RW; Stratford IJ
    Int J Cancer; 2014 Aug; 135(4):820-9. PubMed ID: 24390981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A conjugate of octamer-binding transcription factor 4 and toll-like receptor 7 agonist prevents the growth and metastasis of testis embryonic carcinoma.
    Lin G; Wang X; Yi W; Zhang C; Xu G; Zhu X; Cai Z; Liu Y; Diao Y; Lin MC; Jin G
    J Transl Med; 2015 May; 13():166. PubMed ID: 25990580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.